ScreenerHero

CNSY Cerenome, Inc.

NAS · US · Healthcare · Biotechnology · cerenome.com
1.635USD+2.83%Mkt Cap: 12.41M $P/E: —

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap12.41M USD
Enterprise Value3.52M USD
Revenue (TTM)4.20M USD
Gross Profit-8.30M USD
Net Income (TTM)-22.39M USD
Revenue/Share0.70 USD
Last Price1.635 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.64
PEG2.45
EV/EBITDA-0.14
EV/Revenue0.84
P/S2.87
P/B2.13
EPS (TTM)-3.36
EPS (Forward)-2.48
52W Range
1.4851% of range23.50
52W High23.50 USD
52W Low1.485 USD
Profitability
Gross Margin-197.57%
Oper. Margin-2203.65%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-560.21%
ROA-137.13%
Growth
Revenue Growth-70.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.77M USD
CapEx (TTM)67.00K USD
FCF Margin-332.38%
FCF Yield-112.58%
Net Debt-8.54M USD
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity0.21
Current Ratio1.37
Quick Ratio1.23
Book Value/Sh0.75 USD
Cash/Share1.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateApr 2, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.75 USD
Upside (mean)+1597.2%
Target Range12.00 USD – 43.00 USD
12.00+1597.2% to mean43.00
# Analysts4
Ownership
Shares Out.7.59M
Float7.50M
Insiders1.98%
Institutions15.71%
Short Interest
Short Ratio8.2d
Short % Float8.62%
Short % Out.8.59%
Shares Short651.89K
Short (prev mo.)624.80K
Technical
SMA 502.801 (-41.6%)
SMA 2005.686 (-71.2%)
Beta1.47
S&P 52W Chg16.45%
Avg Vol (30d)136.39K
Avg Vol (10d)260.14K
Technical Indicators
RSI (14)26.7
MACD-0.3743
MACD Signal-0.3872
MACD Hist.+0.0128
BB Upper2.604 USD
BB Middle1.990 USD
BB Lower1.376 USD
BB Width61.66%
ATR (14)0.2187 USD
Vol Ratio (20d)0.63x